Recently identified inhibitors of EZH2 [68], [69] and hopefully soon to be identified inhibitors of MMSET will allow us to determine the therapeutic effects of these targeted therapies on a number of cancer subtypes, including patients with t(4;14) translocations. The gene discussed is NSD2; the disease is cancer.